Alps Advisors Inc Kal Vista Pharmaceuticals, Inc. Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$8.95 - $11.35 $1,986 - $2,519	222 Added 0.88%	25,338 $244,000
Q2 2023 Aug 14, 2023	BUY	$7.73 - $10.57 $194,146 - $265,476	25,116 New	25,116 $226,000
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $11,110 - $18,984	-1,128 Reduced 7.75%	13,433 $195,000
Q2 2022 Aug 11, 2022	SELL	$8.16 - $15.1 $86,969 - $160,935	-10,658 Reduced 42.26%	14,561 $143,000
Q1 2022 May 16, 2022	SELL	$11.2 - $16.97 $34,216 - $51,843	-3,055 Reduced 10.8%	25,219 $372,000
Q4 2021 Feb 09, 2022	BUY	$12.36 - $18.28 $349,466 - $516,848	28,274 New	28,274 $374,000
Q4 2020 Feb 03, 2021	SELL	$12.88 - $19.47 $293,947 - $444,344	-22,822 Closed	0 $0
Q3 2020 Nov 04, 2020	SELL	$9.83 - $13.99 $15,020 - $21,376	-1,528 Reduced 6.28%	22,822 $287,000
Q2 2020 Aug 05, 2020	SELL	$6.75 - $12.89 $54,270 - $103,635	-8,040 Reduced 24.82%	24,350 $295,000
Q1 2020 May 06, 2020	SELL	$5.8 - $18.56 $21,889 - $70,045	-3,774 Reduced 10.44%	32,390 $248,000
Q4 2019 Feb 07, 2020	BUY	$10.31 - $17.81 $372,850 - $644,080	36,164 New	36,164 $644,000

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $220M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.